Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Short-term Investments data on record, last reported at $759.0 million in Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $759.0 million; the TTM value through Dec 2025 reached $759.0 million, changed N/A, while the annual FY2025 figure was $759.0 million, N/A changed from the prior year.
  • Short-term Investments reached $759.0 million in Q4 2025 per RCUS's latest filing, up from $593.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $900.1 million in Q2 2022 and bottomed at $345.2 million in Q3 2021.
  • Average Short-term Investments over 5 years is $653.4 million, with a median of $664.8 million recorded in 2022.
  • The widest YoY moves for Short-term Investments: up 382.29% in 2021, down 38.42% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $351.0 million in 2021, then soared by 128.77% to $803.0 million in 2022, then decreased by 21.3% to $632.0 million in 2023, then surged by 40.51% to $888.0 million in 2024, then decreased by 14.53% to $759.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $759.0 million in Q4 2025, $593.0 million in Q3 2025, and $663.0 million in Q2 2025.